iPSC Haplobank: Building the Immunological Foundation for Regenerative Medicine
These cells can differentiate into virtually any tissue type, enabling therapies that address genetic diseases, tissue damage, and other chronic conditions. However, a critical bottleneck remains: immune rejection. The solution? iPSC haplobanks—curated repositories of clinical-grade iPSC lines from donors with homozygous human leukocyte antigen (HLA) haplotypes. These banks aim to maximize compatibility and reduce the need for immunosuppression in allogeneic cell therapies.
What Is an iPSC Haplobank?
An iPSC haplobank is a specialized biobank of iPSC lines derived from HLA-homozygous donors. These donors possess identical alleles at key immune loci such as HLA-A, HLA-B, and HLA-DRB1. By selecting common homozygous haplotypes within a given population, a relatively small number of iPSC lines can cover a large percentage of individuals—thus enhancing immune matching and clinical applicability for off-the-shelf therapies
Why Haplobanking Matters
Immune Compatibility
Matching donor and recipient at primary HLA loci reduces the risk of graft rejection. Unlike personalized autologous iPSC manufacturing, haplobank lines can be produced once and used repeatedly to immunologically compatible patients.
Scalability and Cost Efficiency
Autologous iPSC therapies are time-intensive and costly (estimated at ~$300,000 per patient line)
SpringerLink
A haplobank approach enables scalability, significantly lowering development costs and delivery times.
Global Reach through Collaboration
Collaborative strategies that pool global HLA data have shown that a well-chosen set of data-driven haplotypes can cover over 60–80% of certain populations. For instance, a global haplobank using 180 common haplotypes could cover up to 81.7% of patients in Sweden and 54.6% in India
Real-World Haplobank Implementations
Japan’s CiRA Haplobank
The Center for iPSC Research and Application (CiRA) established a clinical-grade haplobank from seven HLA-homozygous donors, resulting in 27 iPSC lines that match approximately 40% of the Japanese population. These lines have already been used in over ten clinical trials
South Korea’s National Haplobank Efforts
Institutions in Korea screened cord blood banks for homozygous donors and created iPSC lines covering the most frequent haplotypes in their population
India’s Efforts
The Centre for Stem Cell Research in India collaborates with cord blood registries to derive iPSC lines from Indian donors with favorable HLA profiles, ensuring population relevance from the outset
Benefits and Limitations
Benefits:
Facilitates immediate access to standardized, HLA-matched cell lines
Reduces time and cost compared to autologous manufacturing
Supports scalable, off‑the‑shelf regenerative therapies
Residual immunogenicity still may require limited immunosuppression
HLA diversity varies geographically—some haplotypes may be rare in certain ethnic groups
Comprehensive coverage requires access to global donor registries and collaboration across countries
Technical and Ethical Considerations
Donor Selection & Genotyping
Selecting donors with homozygous HLA haplotypes requires screening thousands of individuals through bone marrow or cord blood registries. These donors should also meet quality, health, and consent standards for therapeutic use
GMP Manufacturing
iPSC lines must be generated under cGMP conditions, with strict testing for genomic stability, sterility, endotoxin, residual reprogramming vector presence, and genetic mutation analysis
Ethical and Regulatory Compliance
Haplobanking initiatives must adhere to local and international regulations involving donor consent, sample distribution, intellectual property, and cross-border use of cell lines.
Immune-Evasive Engineering
As a complementary strategy, creating universal or hypo-immunogenic iPSC lines via gene editing—knocking out HLA class I/II and overexpressing immune regulatory molecules—can broaden coverage and reduce rejection risk
Final Thoughts: Enabling Regenerative Medicine at Scale
At Xellera Therapeutics, we are pioneering GMP-grade iPSC haplobanking in the Asia-Pacific region, starting with donors from Southern China. Our goal is to offer immunologically matched, off-the-shelf cellular therapies to patients in need—reducing rejection risk and accelerating clinical impact. By integrating global HLA insights, cGMP processes, and rigorous regulatory standards, Xellera stands ready to support the next wave of safe and scalable iPSC-based therapeutics